Radioisotopes are foundational to medicine, fusion power, and industry. Most are produced in aging nuclear reactors, many over 50 years old and nearing retirement by the 2030s. Rising demand, limited supply, and emerging alternative production approaches may unlock scalable, high-efficiency, high-purity isotope production with venture-scale potential.